Primary Tumor Resection Decelerates Disease Progression in an Orthotopic Mouse Model of Metastatic Prostate Cancer.
cytoreductive primary tumor removal
metastases
oligometastatic prostate cancer
orthotopic mouse model
radical prostatectomy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
31 Jan 2022
31 Jan 2022
Historique:
received:
06
01
2022
revised:
24
01
2022
accepted:
27
01
2022
entrez:
15
2
2022
pubmed:
16
2
2022
medline:
16
2
2022
Statut:
epublish
Résumé
Radical prostatectomy in oligometastatic prostate cancer is a matter of intense debate. Besides avoiding local complications, it is hypothesized that primary tumor resection may result in better oncological outcomes. The aim of our study was to analyze the effect of primary tumor resection on disease progression in an orthotopic prostate cancer mouse model. First, the optimal time point for primary tumor resection, when metastases have already occurred, but the primary tumor is still resectable, was determined as 8 weeks after inoculation of 5 × 10
Identifiants
pubmed: 35159004
pii: cancers14030737
doi: 10.3390/cancers14030737
pmc: PMC8833735
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : European Association of Urology
ID : EAU RF Seeding Grant 2018
Références
Lancet. 2020 Apr 11;395(10231):1208-1216
pubmed: 32209449
Eur Urol Focus. 2021 Sep;7(5):951-954
pubmed: 33384271
Clin Exp Metastasis. 2016 Apr;33(4):325-37
pubmed: 26873136
Urology. 2017 Aug;106:146-152
pubmed: 28435034
Curr Opin Urol. 2020 Jan;30(1):90-97
pubmed: 31724996
Nat Rev Urol. 2021 Feb;18(2):79-92
pubmed: 33328650
Eur Urol. 2018 Mar;73(3):482-484
pubmed: 29150358
Nat Rev Urol. 2020 Jan;17(1):11-27
pubmed: 31827264
World J Urol. 2017 Apr;35(4):567-577
pubmed: 27502935
Sci Rep. 2020 Jul 28;10(1):12575
pubmed: 32724081
Eur Urol. 2014 Oct;66(4):704-10
pubmed: 24931622
J Clin Oncol. 2002 Mar 1;20(5):1248-59
pubmed: 11870167
Eur Urol. 2014 Jun;65(6):1058-66
pubmed: 24290503
Nature. 2015 Apr 16;520(7547):353-357
pubmed: 25830880
Prostate. 2011 Nov;71(15):1668-79
pubmed: 21432867
Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3439-43
pubmed: 7724580
J Urol. 2011 Jan;185(1):60-6
pubmed: 21074201
Prostate. 2015 Oct;75(14):1526-37
pubmed: 26074274
Eur Urol Focus. 2017 Dec;3(6):646-649
pubmed: 28753877
Lancet. 2018 Dec 1;392(10162):2353-2366
pubmed: 30355464
J Urol. 2006 Oct;176(4 Pt 1):1292-8
pubmed: 16952615
World J Urol. 2021 Sep;39(9):3231-3237
pubmed: 33502558
Prostate. 2018 Jun;78(9):664-675
pubmed: 29572953
Urologe A. 2015 Nov;54(11):1613-6
pubmed: 26573673
Cancer Res. 2006 Dec 1;66(23):11089-93
pubmed: 17145848
Dev Cell. 2019 May 6;49(3):347-360
pubmed: 31063754
Urologe A. 2017 Nov;56(11):1430-1434
pubmed: 28983651
J Immunol Methods. 2006 May 30;312(1-2):12-9
pubmed: 16624319
BJU Int. 2019 Jan;123(1):58-64
pubmed: 29772100
Prostate. 2013 Sep;73(12):1251-62
pubmed: 23740600
Prostate. 2017 May;77(6):654-671
pubmed: 28156002
Oncol Rep. 2015 Dec;34(6):2837-44
pubmed: 26503286